Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 145, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112385
Keywords
Chemically Modified mRNA; COVID-19; Vaccination; Chronic diseases; Cancer; Diabetes
Funding
- Qatar University [QUCG-CPH-20/21-4, QUCG-CPH-21/22-1]
Ask authors/readers for more resources
Chemically modified mRNA is a promising approach for producing biopharmaceutical agents, with applications in addressing epidemics and treating a variety of chronic diseases, such as metabolic disorders, cancer, musculoskeletal disorders, respiratory conditions, cardiovascular diseases, and liver diseases.
Chemically modified mRNA represents a unique, efficient, and straightforward approach to produce a class of biopharmaceutical agents. It has been already approved as a vaccination-based method for targeting SARS-CoV-2 virus. The COVID-19 pandemic has highlighted the prospect of synthetic modified mRNA to efficiently and safely combat various diseases. Recently, various optimization advances have been adopted to overcome the limitations associated with conventional gene therapeutics leading to wide-ranging applications in different disease conditions. This review sheds light on emerging directions of chemically modified mRNAs to prevent and treat widespread chronic diseases, including metabolic disorders, cancer vaccination and immunotherapy, musculoskeletal disorders, respiratory conditions, cardiovascular diseases, and liver diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available